Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients

Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients

In this study we evaluated both~ K- and N-<i>RAS</i> mutations in plasma samples from patients with metastatic colorectal cancer by means of the BEAMing technology, and we assessed their diagnostic performance compared to <i>RAS</i> analyses performed on tissue. The sensitivi...

Full description

Bibliographic Details
Main Authors:	Elena Lastraioli, Alessandra Bettiol, Jessica Iorio, Elvira Limatola, Daniele Checcacci, Erica Parisi, Cristina Bianchi, Annarosa Arcangeli, Mauro Iannopollo, Francesco Di Costanzo, Marco Di Lieto
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Cells
Subjects:	<i>KRAS</i> <i>NRAS</i> liquid biopsy metastatic colorectal cancer
Online Access:	https://www.mdpi.com/2073-4409/12/11/1458

Similar Items

Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database
by: Shuhei Suzuki, et al.
Published: (2024-12-01)

<i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> Hot-Spot Mutations in Relation to Sidedness of Primary Colorectal Cancer: A Retrospective Cohort Study
by: Omer Abdelgadir, et al.
Published: (2025-01-01)

Mortality Outcome Associated with Specific <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> Hot-Spot Mutations in Metastatic Colorectal Cancer Patients: A Retrospective Cohort Study
by: Omer Abdelgadir, et al.
Published: (2025-02-01)

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
by: Gouvas Nikolaos, et al.
Published: (2019-07-01)

Molecular genetic characteristics of colorectal cancer depending on the status of microsatellite instability
by: K. A. Oganyan, et al.
Published: (2022-06-01)

Second-line panitumumab as a triweekly dose for patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer: a single-institution experience
by: Mohamed A. Daoud, et al.
Published: (2016-03-01)

Prognostic Roles of <i>BRAF</i>, <i>KIT</i>, <i>NRAS</i>, <i>IGF2R</i> and <i>SF3B1</i> Mutations in Mucosal Melanomas
by: Joanna P. Wróblewska, et al.
Published: (2021-08-01)

RAS oncogenes direct metastasis
by: Magda Spella, et al.
Published: (2017-09-01)

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)

IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
by: Praveen Guruvaiah, et al.
Published: (2024-07-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
by: Nianyi Li, et al.
Published: (2023-07-01)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Relationship between KRAS and NRAS factors with clinicopathologic findings in patients with metastatic colon cancer
by: Hamid Saeidi Saedi, et al.
Published: (2023-03-01)

Molecular characterization of multiple myeloma
by: Buse Zeren Kiremitci, et al.
Published: (2022-07-01)

FREQUENCY OF NRAS AND KRAS GENES IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS
by: Sidra Barlas, et al.
Published: (2020-04-01)

K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice
by: Pui Yan Siak, et al.
Published: (2021-02-01)

Case report of metastatic colorectal cancer associated with <i>KRAS</i> A146V and A59G mutations
by: O. I. Kit, et al.
Published: (2023-07-01)

Clinicopathological Characteristics and Mutational Landscape of <i>APC</i>, <i>HOXB13,</i> and <i>KRAS</i> among Rwandan Patients with Colorectal Cancer
by: Felix Manirakiza, et al.
Published: (2023-05-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
by: Tianyou Yang, et al.
Published: (2019-05-01)

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
by: Meryem Jafari, et al.
Published: (2022-11-01)

Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis
by: Ofra Novoplansky, et al.
Published: (2022-05-01)

Molecular Markers and Targets in Melanoma
by: Cristina Teixido, et al.
Published: (2021-09-01)

Comprehensive Analysis of the Expression and Clinical Significance of RAS Family Members in Non-Small Cell Lung Cancer Based on Bioinformatics Data and the A549 Cell Line Model
by: Milena Pązik, et al.
Published: (2022-12-01)

Association between <i>KRAS</i> and <i>PIK3CA</i> Mutations and Progesterone Resistance in Endometriotic Epithelial Cell Line
by: Kosuke Kanno, et al.
Published: (2024-04-01)

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations
by: Abhimanyu Tushir, et al.
Published: (2025-01-01)

NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study
by: Kuan-Jou Wu, et al.
Published: (2021-05-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series
by: Youssef Mahdi, et al.
Published: (2023-06-01)

Somatic mutations in colorectal cancer: regional experience
by: Nikolai A. Ognerubov, et al.
Published: (2022-07-01)

CT-Based Radiomics to Predict <i>KRAS</i> Mutation in CRC Patients Using a Machine Learning Algorithm: A Retrospective Study
by: Jacobo Porto-Álvarez, et al.
Published: (2023-07-01)

Prognostic Role of <i>KRAS G12C</i> Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Durgesh Wankhede, et al.
Published: (2023-09-01)

Efficacy of Immunotherapy in Second-Line Treatment of <i>KRAS</i>-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
by: Magdalena Knetki-Wróblewska, et al.
Published: (2022-12-01)

Association of <i>KRAS</i> G12C Status with Age at Onset of Metastatic Colorectal Cancer
by: Marcelo Sunagua Aruquipa, et al.
Published: (2024-02-01)

Active Compound of <i>Pharbitis</i> Semen (<i>Pharbitis nil</i> Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression
by: Jisu Song, et al.
Published: (2020-06-01)

Crucial Role of Oncogenic <i>KRAS</i> Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications
by: Anabela Ferreira, et al.
Published: (2022-07-01)

Molecular-genetic mechanisms of the signal cascade RAS-RAF-MEK-ERK associated with the development of the tumor process and the purpose of targeted drugs for colorectal cancer
by: A. N. Toropovsky, et al.
Published: (2021-08-01)